Drugs in the Pipeline
Tezepelumab Cuts Exacerbations in Severe Asthma Trial
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Your search for oral corticosteroids returned 176 results
Drugs in the Pipeline
Benralizumab Reduces OCS Use in Severe Asthma Trial
Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…
News
Corticosteroid Exposure Affects Bone Health in Asthma Patients
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
CHEST 2020
Bronchial Thermoplasty Improves Asthma Control, Reduces ICS Need
The use of bronchial thermoplasty resulted in improvements in asthma control and reductions in the use of corticosteroid maintenance therapies in patients with asthma.
News
Dupilumab Reduces Severe Asthma Attacks in Pediatric Trial
The randomized, double-blind, placebo-controlled VOYAGE trial included 408 children aged 6 to 11 years with uncontrolled persistent asthma.
Features
ATS: Clinical Practice Guidelines on the Pharmacologic Management of COPD
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
News
Ortikos Now Available for Mild to Moderate Crohn Disease
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
News
Breztri Aerosphere Approved as Triple-Combination Therapy Inhaler for COPD
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
News
Oral Corticosteroid Bursts Carry Risk for Severe Adverse Events
Highest rates of adverse events seen within first month after initiating short course of oral steroids.
News
Dupixent Prefilled Pen Approval Provides Additional Administration Option
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
